Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India
Influenza and Other Respiratory Viruses · 2026-05 · 20 (5)
DOI: 10.1111/irv.70264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 30.04.2026. Verfasst von Anand Krishnan und 19 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Immunization Programs, Influenza Vaccines, Influenza, Human. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCIRD CDC HHS, CDC HHS, Centers for Disease Control and Prevention.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Background
In India, no publicly funded seasonal influenza immunization is ongoing, partly because cost‐effectiveness is yet to be established. We estimate the cost‐effectiveness and budgetary impact of introducing seasonal influenza vaccination among adults aged ≥ 60 years in India, a known high‐risk group.
Methods
Estimates of disease burden including disability adjusted life years (DALYs) were generated from 3‐year community cohorts and hospital‐based study set up at four sites to estimate incidence of symptomatic acute respiratory infections (ARI), health care utilization, costs and outcomes and applied to India's 2021 estimated population. We used a decision analysis model from an abridged societal perspective for implementation of an inactivated trivalent influenza vaccination programme for older adults (aged ≥ 60 years) using either facility‐based or outreach‐based approaches. We estimated incremental cost‐effectiveness ratio (ICER) per DALY averted and used India's per capita gross domestic product of US$ 2238 for 2021 as the cost‐effectiveness threshold. We performed deterministic and probabilistic sensitivity analyses. We also estimated ICER for immunizing all those above 65 years or with comorbidities. Using financial cost of the vaccination programme and the direct medical cost of disease averted we estimated its budgetary impact.
Results
In 2021, older adults in India had 5.3 (95% CI: 3.6–7.7) million influenza‐ARIs resulting in 36,149 (95% CI: 30,076–43,268) hospitalizations and 84,613 (95% CI: 39,895–155,454) deaths. It amounted to a total of 974,019 DALYs and US$ 66.6 million. As compared with no vaccination, facility‐based and outreach‐based influenza vaccination had an ICER of US$1979 and US$1851, respectively, below the cost‐effectiveness threshold. In all sensitivity and scenario analyses, ICER estimates were below the threshold and vaccinating those above 60 years with specified comorbidities using a passive approach was found to be most cost‐effective with least budgetary impact.
Conclusion
Annually vaccinating older adults against influenza was found to be cost‐effective in the majority of scenarios considered in the study. Given the budgetary implication, it might be prudent to focus on those with co‐morbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India.
- Influenza Program, US Centers for Disease Control and Prevention, New Delhi, India.
- Coronavirus and Other Respiratory Viruses Division, National Center of Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Indian Council for Medical Research, National Institute of Epidemiology, Chennai, India.
- Indian Council for Medical Research, National Institute of Research in Bacterial Infection, Kolkata, India.
- Indian Council for Medical Research, National Institute of Virology, Pune, India.
ORCID-Profile: Aslesh Ottapura Prabhakaran, Avinash Choudekar
Förderung
- NCIRD CDC HHS
- CDC HHS
- Centers for Disease Control and Prevention
Zitieren
APA
Krishnan, A., Prabhakaran, A. O., Shekhawat, K., Ortega-Sanchez, I. R., Kumar, R., Amarchand, R., Rajkumar, P., Kanungo, S., Bhardwaj, S. D., Gopal, G., Purushothaman, G. K. C., Potdar, V., Chakrabarti, A. K., Gharpure, R., Choudekar, A., Lafond, K. E., Dar, L., Saha, S., Tan, K. R., & Azziz-Baumgartner, E. (2026). Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India. Influenza and Other Respiratory Viruses, 20(5). https://doi.org/10.1111/irv.70264
Vancouver
Krishnan A, Prabhakaran AO, Shekhawat K, Ortega-Sanchez IR, Kumar R, Amarchand R, et al. Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India. Influenza and Other Respiratory Viruses. 2026;20(5). doi:10.1111/irv.70264
BibTeX
@article{Krishnan2026,
author = {Krishnan, Anand and Prabhakaran, Aslesh Ottapura and Shekhawat, Kusum and Ortega-Sanchez, Ismael R and Kumar, Rakesh and Amarchand, Ritvik and Rajkumar, Prabu and Kanungo, Suman and Bhardwaj, Sumit Dutt and Gopal, Giridara and Purushothaman, Girish Kumar Chethrapilly and Potdar, Varsha and Chakrabarti, Alok Kumar and Gharpure, Radhika and Choudekar, Avinash and Lafond, Kathryn E and Dar, Lalit and Saha, Siddhartha and Tan, Kathrine R and Azziz-Baumgartner, Eduardo},
title = {Burden of Influenza and Cost‐Effectiveness Analysis of Introduction of an Influenza Vaccination Programme Among Older Adults in India},
journal = {Influenza and Other Respiratory Viruses},
year = {2026},
volume = {20},
number = {5},
doi = {10.1111/irv.70264}
}
EUVIMED